Login to Your Account



Clinic Roundup


Tuesday, April 16, 2013

• NeuroDerm Ltd., of Ness Ziona, Israel, said enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a treatment for Parkinson's disease. ND0612 is a levodopa/carbidopa liquid formula under development for continuous sub-cutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription